{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-328470","form_type":"8-K/A","ticker":"NBIX","cik":"0000914475","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2026-07-31T20:05:13+00:00","discovered_at":"2026-07-31T20:06:05.847925+00:00","generated_at":"2026-07-31T20:06:13.291751+00:00","sec_items":["9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Neurocrine files pro forma financials for Soleno acquisition; combined net income $294M for H1 2026","bullets":["Pro forma combined net income $294.0M ($2.92 basic EPS) for six months ended June 30, 2026.","Pro forma combined net income $324.5M ($3.26 basic EPS) for year ended Dec 31, 2025.","Acquisition of Soleno for $53/share added VYKAT XR for Prader-Willi syndrome; funded with $600M credit facility draw, fully repaid by June 30.","Soleno contributed $94.6M revenue in Q1 2026 and $190.4M in FY2025.","Preliminary purchase price allocation includes $168.2M inventory step-up amortized over 4-6 years."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-328470","json":"https://secwatch.observer/filing/0001193125-26-328470.json","markdown":"https://secwatch.observer/filing/0001193125-26-328470.md","text":"https://secwatch.observer/filing/0001193125-26-328470.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/914475/000119312526328470/0001193125-26-328470-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/914475/000119312526328470/d73154d8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-31T20:06:13.291751+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}